How to buy Cerecor stock | $2.64

Cerecor Inc is a biotechnology business based in the US. Cerecor shares (CERC) are listed on the NASDAQ and all prices are listed in US Dollars. Cerecor employs 18 staff and has a trailing 12-month revenue of around USD$6.9 million.

How to buy shares in Cerecor

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Cerecor. Find the stock by name or ticker symbol: CERC. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cerecor reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.64, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cerecor, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Cerecor. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cerecor share price

Use our graph to track the performance of CERC stocks over time.

Cerecor shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$2.64
52-week range	USD$1.52 - USD$6.19
50-day moving average	USD$2.4303
200-day moving average	USD$2.5527
Wall St. target price	USD$11
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.894

Buy Cerecor shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Cerecor stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cerecor Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cerecor price performance over time

Historical closes compared with the close of $2.64 from 2020-12-04

1 week (2020-11-25)	9.09%
1 month (2020-11-05)	26.32%
3 months (2020-09-04)	18.39%
6 months (2020-06-05)	-3.30%

1 year (2019-12-05)	-21.66%
2 years (2018-12-04)	-22.58%
3 years (2017-12-05)	60.00%
5 years (2015-12-04)	-25.63%

Cerecor financials

Revenue TTM	USD$6.9 million
Gross profit TTM	USD$-4,879,126
Return on assets TTM	-25.19%
Return on equity TTM	-127.56%
Profit margin	0%
Book value	$0.623
Market capitalisation	USD$182.3 million

TTM: trailing 12 months

Shorting Cerecor shares

There are currently 1.4 million Cerecor shares held short by investors – that's known as Cerecor's "short interest". This figure is 6.4% down from 1.5 million last month.

There are a few different ways that this level of interest in shorting Cerecor shares can be evaluated.

Cerecor's "short interest ratio" (SIR)

Cerecor's "short interest ratio" (SIR) is the quantity of Cerecor shares currently shorted divided by the average quantity of Cerecor shares traded daily (recently around 422958.02469136). Cerecor's SIR currently stands at 3.24. In other words for every 100,000 Cerecor shares traded daily on the market, roughly 3240 shares are currently held short.

However Cerecor's short interest can also be evaluated against the total number of Cerecor shares, or, against the total number of tradable Cerecor shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cerecor's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cerecor shares in existence, roughly 20 shares are currently held short) or 0.0304% of the tradable shares (for every 100,000 tradable Cerecor shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cerecor.

Find out more about how you can short Cerecor stock.

Cerecor share dividends

We're not expecting Cerecor to pay a dividend over the next 12 months.

Cerecor share price volatility

Over the last 12 months, Cerecor's shares have ranged in value from as little as $1.52 up to $6.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerecor's is 1.679. This would suggest that Cerecor's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cerecor overview

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.

Frequently asked questions

• What percentage of Cerecor is owned by insiders or institutions?

  Currently 13.822% of Cerecor shares are held by insiders and 77.074% by institutions.

• How many people work for Cerecor?

  Latest data suggests 18 work at Cerecor.

• When does the fiscal year end for Cerecor?

  Cerecor's fiscal year ends in December.

• Where is Cerecor based?

  Cerecor's address is: 540 Gaither Road, Rockville, MD, United States, 20850

• What is Cerecor's CUSIP number?

  Cerecor's Committee on Uniform Securities Identification Procedures number is: 15671L109